Extended safety check for rare genetic disease therapy
NCT ID NCT06031259
Summary
This study continues monitoring the safety of two drugs (idursulfase-IT and elaprase) for children and adults with Hunter syndrome who have cognitive impairment. It follows participants from two previous trials for nearly five years to track any side effects from the monthly spinal injections and weekly IV infusions. The goal is to understand the long-term safety profile of this treatment combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTER SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hopital Femme Mere Enfant
Bron, Auvergne-Rhône-Alpes, 02 69229, France
-
Hospital for Sick Children
Toronto, Ontario, M5G1X8, Canada
-
M.A.G.I.C. Clinic
Calgary, Alberta, T2E 7Z4, Canada
-
University of British Columbia
Vancouver, British Columbia, V6T1Z3, Canada
Conditions
Explore the condition pages connected to this study.